{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3TC&page=7",
    "query": {
      "intervention": "3TC",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 312,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3TC&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3TC&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T03:19:23.544Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00410202",
      "title": "Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B, Chronic"
      ],
      "interventions": [
        {
          "name": "Entecavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Adefovir",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 629,
      "start_date": "2008-03",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2013-11-21",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00410202"
    },
    {
      "nct_id": "NCT00141284",
      "title": "An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "nelfinavir 1,250 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Zidovudine 300 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine 150 mg twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2005-10",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Miami, Florida • Shreveport, Louisiana + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141284"
    },
    {
      "nct_id": "NCT00050908",
      "title": "Blood Vessel Function in HIV-Infected Patients Taking Anti-HIV Drugs",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 75,
      "start_date": null,
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2013-07-29",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • San Diego, California • Honolulu, Hawaii + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00050908"
    },
    {
      "nct_id": "NCT02263326",
      "title": "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Continue current antiretroviral regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Babafemi Taiwo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-14",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263326"
    },
    {
      "nct_id": "NCT00491556",
      "title": "Preservation and Expansion of T-cell Subsets Following HAART De-intensification to Atazanavir/Ritonavir (ATV/r)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Early Initiation of Highly Active Anti-Retroviral Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Standard Care",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "18 Years to 24 Years"
      },
      "enrollment_count": 102,
      "start_date": "2007-10",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 22,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00491556"
    },
    {
      "nct_id": "NCT01605084",
      "title": "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Optimized NRTI backbone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-06-30",
      "completion_date": "2014-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-12-19",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01605084"
    },
    {
      "nct_id": "NCT00084136",
      "title": "Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Didanosine (enteric-coated)",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine/Tenofovir disoproxil fumarate",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine/Zidovudine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1571,
      "start_date": "2005-05",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2018-10-10",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 27,
      "location_summary": "Los Angeles, California • Torrance, California • Denver, Colorado + 16 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00084136"
    },
    {
      "nct_id": "NCT04283656",
      "title": "Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Transgender Health",
        "Gender Dysphoria",
        "Transgender Women",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Doravirine/Lamivudine/Tenofovir",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone 100mg",
          "type": "DRUG"
        },
        {
          "name": "Estradiol 2mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 8,
      "start_date": "2022-01-04",
      "completion_date": "2022-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04283656"
    },
    {
      "nct_id": "NCT00135369",
      "title": "Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "stavudine extended-release, lamivudine, efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2002-09",
      "completion_date": "2005-07",
      "has_results": false,
      "last_update_posted_date": "2011-04-25",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 46,
      "location_summary": "Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 43 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00135369"
    },
    {
      "nct_id": "NCT00100581",
      "title": "Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Efavirenz",
          "type": "DRUG"
        },
        {
          "name": "Lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir disoproxil fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": null,
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-11-09T03:19:23.544Z",
      "location_count": 2,
      "location_summary": "New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00100581"
    }
  ]
}